Virasoft

Virasoft

The Virasoft software improves digital pathology processes which can be analyzed for clinical diagnosis.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
investor

€0.0

round
investor investor

€0.0

round
N/A

€0.0

round
investor

€0.0

Valuation: €0.0

round
*

N/A

Early VC
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD202020212023
Revenues000000000000
% growth-5 %-
EBITDA000000000000
Profit000000000000
EV000000000000
EV / revenue00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x
R&D budget000000000000

Source: Dealroom estimates

Notes (0)
More about Virasoft
Made with AI
Edit

Virasoft operates within the health-tech sector, providing digital pathology and artificial intelligence solutions tailored for cancer diagnosis and research. The company was founded in 2017 by two childhood friends and engineers, Gökhan Hatipoğlu and Samet Tunc, who were personally motivated by the high incidence of cancer in their hometowns, affected by the Chernobyl disaster. This personal experience fueled their mission to use technology to improve the speed and accuracy of cancer diagnostics.

The firm's business model centers on delivering a comprehensive suite of tools for pathology laboratories, including academic institutions, private, and public hospitals. Its offerings are designed to digitize and streamline the entire pathology workflow, from sample accessioning to final reporting. Virasoft generates revenue by providing these workflow solutions, AI-powered decision support algorithms, and telepathology platforms to its clients. The company's solutions are compatible with all scanner devices, offering a flexible and modular approach that can be customized to a lab's specific needs. Since 2019, its products have been used to analyze approximately 400,000 cases annually across more than 20 institutions.

Virasoft's product portfolio includes the Anatomic Pathology Laboratory Information System (APLIS) known as VIRAPIS, which manages lab processes with barcode tracking. Its Image Management System (IMS), VIRASIGHT, is a web-based, CE-IVD certified application for storing, managing, and annotating whole slide images. The company has also developed AI-based algorithms to assist pathologists in improving diagnostic accuracy. One of its research papers, "Tubule-U-Net," was recognized as a top downloaded cancer research paper in Scientific Reports in 2023. Headquartered in New York with an R&D office in Istanbul, Virasoft has secured $4.58 million in funding from investors including Acibadem Healthcare, AK Asset Management, and Türk Telekom Ventures, and was part of the CDL-Seattle 2024/25 Computational Health cohort.

Keywords: digital pathology, AI in healthcare, cancer diagnosis, pathology workflow, laboratory information system, image management system, telepathology, computational pathology, whole slide imaging, decision support algorithms, health-tech, oncology diagnostics, VIRAPIS, VIRASIGHT, pathology software, cancer research tools, medical imaging AI, anatomic pathology, clinical decision support, AI pathology

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo